These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 17804114)

  • 1. Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer.
    Huang YJ; Liu SF; Wang CJ; Huang MY
    Lung Cancer; 2008 Mar; 59(3):407-10. PubMed ID: 17804114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
    Kim JE; Lee DH; Choi Y; Yoon DH; Kim SW; Suh C; Lee JS
    Lung Cancer; 2009 Sep; 65(3):351-4. PubMed ID: 19157632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
    Lind JS; Lagerwaard FJ; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
    Namba Y; Kijima T; Yokota S; Niinaka M; Kawamura S; Iwasaki T; Takeda Y; Kimura H; Okada T; Yamaguchi T; Nakagawa M; Okumura Y; Maeda H; Ito M
    Clin Lung Cancer; 2004 Sep; 6(2):123-8. PubMed ID: 15476598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
    Bai H; Han B
    Am J Clin Oncol; 2013 Apr; 36(2):110-5. PubMed ID: 22391431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant drug interaction: phenytoin toxicity due to erlotinib.
    Grenader T; Gipps M; Shavit L; Gabizon A
    Lung Cancer; 2007 Sep; 57(3):404-6. PubMed ID: 17383767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metastasis responding to gefitinib alone.
    Poon AN; Ho SS; Yeo W; Mok TS
    Oncology; 2004; 67(2):174-8. PubMed ID: 15539923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
    Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
    Gow CH; Chien CR; Chang YL; Chiu YH; Kuo SH; Shih JY; Chang YC; Yu CJ; Yang CH; Yang PC
    Clin Cancer Res; 2008 Jan; 14(1):162-8. PubMed ID: 18172267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.
    Kim JH; Kim HS; Choi JS; Lee KM; Shin YC; Ahn BM; Choi DR; Kwon JH; Park S; Kim HY; Jung JY; Kim HJ; Song HH; Zang DY
    Lung Cancer; 2009 Apr; 64(1):121-3. PubMed ID: 19022521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
    Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
    Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
    Jamal-Hanjani M; Spicer J
    Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
    Bartolotti M; Franceschi E; Brandes AA
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1429-35. PubMed ID: 23249107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib induced skin rash spares skin in previous radiotherapy field.
    Mitra SS; Simcock R
    J Clin Oncol; 2006 Jun; 24(16):e28-9. PubMed ID: 16735697
    [No Abstract]   [Full Text] [Related]  

  • 17. [Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
    Mairovitz A; Staub E; Le Floch H; Rivière F; Bonnichon A; Margery J; Vaylet F
    Rev Pneumol Clin; 2009 Oct; 65(5):318-21. PubMed ID: 19878809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
    Olmez I; Donahue BR; Butler JS; Huang Y; Rubin P; Xu Y
    Lung Cancer; 2010 Nov; 70(2):174-9. PubMed ID: 20207442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
    Nakamichi S; Kubota K; Horinouchi H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Tamura T
    Jpn J Clin Oncol; 2013 Apr; 43(4):422-5. PubMed ID: 23410901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of chemotherapy on brain metastasis.
    Lee SH
    Prog Neurol Surg; 2012; 25():110-4. PubMed ID: 22236672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.